Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Praxis Precision Medicines, Inc. (NASDAQ: PRAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Praxis is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and its filings offer detailed insight into the development and financing of its precision neuroscience portfolio.
Through Forms 8-K, Praxis reports material events such as topline clinical results, regulatory interactions and capital markets transactions. Recent 8-K filings describe positive Phase 3 Essential3 data for ulixacaltamide in essential tremor, EMBOLD study outcomes for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), and RADIANT study data for vormatrigine in focal onset seizures and generalized epilepsy. Other 8-Ks outline pre-New Drug Application (NDA) meetings with the U.S. Food and Drug Administration (FDA), alignment on registrational pathways for elsunersen in early-onset SCN2A-DEE, and details of underwritten public offerings and at-the-market equity programs.
Investors can also use this page to monitor filings related to Praxis’ common stock listing on The Nasdaq Global Select Market under the symbol PRAX, shareholder meeting results, and executive compensation or governance matters disclosed in proxy-related documents. As Praxis advances ulixacaltamide, vormatrigine, relutrigine and elsunersen, its periodic and current reports are expected to discuss clinical progress, regulatory designations, risk factors and use of proceeds from financings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each PRAX filing. Real-time updates from EDGAR, combined with accessible explanations of complex disclosures, make this page a practical starting point for analyzing Praxis Precision Medicines’ regulatory and financial reporting history.
Praxis Precision Medicines, Inc. (PRAX) reported a routine insider equity award through a Form 4 filed on 27 June 2025. Director Jeffrey Chodakewitz received a grant of 10,520 stock options on 26 June 2025 at an exercise price of $44.04 per share. The options vest in 12 equal monthly installments over one year beginning the grant date and carry an expiration date of 26 June 2035. No open-market purchases or sales of common stock were disclosed, and Mr. Chodakewitz’s direct derivative holdings after the transaction total 10,520 options. The filing reflects a standard compensation-related award rather than a change in the director’s economic exposure to outstanding common shares.
Praxis Precision Medicines, Inc. (PRAX) – Form 4 Insider Transaction
Director Merit Ester Cudkowicz reported the grant of 10,520 stock options on 26 June 2025. The options carry an exercise price of $44.04 and expire on 26 June 2035. Ownership is recorded as direct.
Vesting schedule: the award vests in 12 equal monthly installments over one year, beginning 26 June 2025, resulting in full vesting by 26 June 2026. Following the grant, the reporting person beneficially owns 10,520 derivative securities; no common-stock transactions were disclosed in Table I.
The filing is routine compensation-related and does not involve any sale or purchase of shares. It primarily signals ongoing alignment of director incentives with shareholder interests and does not immediately affect PRAX’s capital structure, earnings, or liquidity.
Praxis Precision Medicines, Inc. (Nasdaq: PRAX) filed a Form 8-K detailing the voting results from its 2025 Annual Meeting held on June 26, 2025. A quorum was present and all three management proposals passed.
- Proposal 1 – Election of Class II Directors: Dr. Jeffrey Chodakewitz was elected with 14,596,188 votes for and 2,998,186 withheld; Dr. Merit Cudkowicz received 17,499,300 votes for and 95,074 withheld. Both directors will serve until the 2028 annual meeting. Broker non-votes for each nominee totaled 778,152.
- Proposal 2 – Auditor Ratification: Ernst & Young LLP was re-appointed as independent registered public accounting firm for FY 2025 with 18,358,636 votes for, 7,630 against and 6,260 abstentions (no broker non-votes).
- Proposal 3 – Say-on-Pay (advisory): Executive compensation was approved with 10,671,320 votes for, 6,919,705 against, 3,349 abstentions and 778,152 broker non-votes.
No additional matters were brought before stockholders. The filing is primarily administrative and does not disclose financial performance, transactions, or strategic changes.